Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 3
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean naddim mn (3 results)?
Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis.
Commons RJ, Rajasekhar M, Allen EN, Yilma D, Chotsiri P, Abreha T, Adam I, Awab GR, Barber BE, Brasil LW, Chu CS, Cui L, Edler P, Gomes MDSM, Gonzalez-Ceron L, Grigg MJ, Hamid MMA, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Longley RJ, Monteiro WM, Pasaribu AP, Poespoprodjo JR, Richmond CL, Rijal KR, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Workman LJ, Tarning J, Stepniewska K, Guerin PJ, Simpson JA, Barnes KI, Price RN; WorldWide Antimalarial Resistance Network Paediatric Primaquine Vivax Study Group. Commons RJ, et al. Lancet Child Adolesc Health. 2024 Nov;8(11):798-808. doi: 10.1016/S2352-4642(24)00210-4. Epub 2024 Sep 24. Lancet Child Adolesc Health. 2024. PMID: 39332427 Free PMC article.
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ; WWARN Vivax Adherence Study Group. Mehdipour P, et al. Malar J. 2023 Oct 10;22(1):306. doi: 10.1186/s12936-023-04725-w. Malar J. 2023. PMID: 37817240 Free PMC article.
Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis.
Edler P, Rajasekhar M, Price DJ, Adam I, Awab GR, Barber BE, Brasil LW, Chamma-Siqueira NN, Chu CS, Cui L, Daher A, Gomes MDSM, Gonzalez-Ceron L, Grigg MJ, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Manning L, Mekonnen DA, Monteiro WM, Moore BR, Nosten F, Pasaribu AP, Pereira DB, Poespoprodjo JR, Pukrittayakamee S, Rijal KR, Saravu K, Siqueira AM, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Yeshiwondim AK, Zuluaga-Idarraga LM, Guerin PJ, Simpson JA, Price RN, Commons RJ; WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group. Edler P, et al. Malar J. 2025 Nov 14;24(1):400. doi: 10.1186/s12936-025-05642-w. Malar J. 2025. PMID: 41239453 Free PMC article.
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, Barber BE, Chu CS, Cui L, Daher A, Gonzalez-Ceron L, Grigg MJ, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Lidia K, Llanos-Cuentas A, Longley RJ, Pereira DB, Pasaribu AP, Pukrittayakamee S, Rijal KR, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, Watson JA, Zuluaga-Idarraga LM, White NJ, Guerin PJ, Simpson JA, Price RN; WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group. Commons RJ, et al. Lancet Infect Dis. 2024 Feb;24(2):172-183. doi: 10.1016/S1473-3099(23)00430-9. Epub 2023 Sep 22. Lancet Infect Dis. 2024. PMID: 37748496 Free PMC article.
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, Awab GR, Baird JK, Bancone G, Barber BE, Grigg MJ, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Llanos-Cuentas A, Pukrittayakamee S, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thriemer K, Watson JA, Guerin PJ, White NJ, Price RN, Commons RJ; WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group. Rajasekhar M, et al. Lancet Infect Dis. 2024 Feb;24(2):184-195. doi: 10.1016/S1473-3099(23)00431-0. Epub 2023 Sep 22. Lancet Infect Dis. 2024. PMID: 37748497 Free PMC article.